Should NPDR patients be treated with anti-VEGF agents?

Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).


Dr Jennifer Sun, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

See more EURETINA coverage